-Spectral joins leading Japanese medical centres in presenting data on
clinical utility of EAA(TM) diagnostic-
TORONTO, Feb. 28 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX: SDI) today announced that it will present new findings demonstrating the clinical utility of its EAA(TM) Endotoxin Activity Assay, the only FDA cleared diagnostic for the measurement of endotoxin, at the 12th Annual Critical Care for Endotoxemia congress. The conference takes place in Fukuoka, Japan from February 28th-29th, 2008 and focuses on the role of endotoxemia in sepsis in critically ill patients. The Company and a number of leading medical centres in Japan including the Tokyo Medical Clinic, Osaka City General Hospital and Iwate Medical University will each present findings using data collected with Spectral's EAA(TM) product that highlight the clinical utility of the diagnostic.
"More than one-third of the presentations being given at this important conference use data collected with our EAA(TM) and highlight the value of our product. With Japan being one of the leading nations that emphasize the importance of endotoxin and its role in sepsis, our unique EAA(TM) diagnostic plays a prominent role in patient care," said Dr. Paul Walker, President and CEO of Spectral Diagnostics. "This data supports our expanded distribution relationship with Toray, which commenced last quarter. Toray's therapeutic column, Toraymyxin, is highly effective in removing endotoxin from the bloodstream and together with EAA(TM) has been recognized in Japan as a valuable combination for the diagnosis, treatment and monitoring of patients with endotoxemia."
Debra Foster, Director of Spectral's Sepsis Program, will present Friday February 29th at 8:30am Japanese Standard Time. Following the conference, the findings presented will be published in the Japan Journal for Critical Care for Endotoxemia.
About Spectral Diagnostics
Spectral is a developer of innovative technologies for comprehensive disease management. Spectral's lead product is its EAA(TM) Endotoxin Activity Assay, the only FDA approved diagnostic for the measurement of endotoxin. Spectral technologies provide accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Spectral is listed on TSX under the symbol SDI.
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this statement.
|SOURCE Spectral Diagnostics Inc.|
Copyright©2008 PR Newswire.
All rights reserved